Anti-VEGF therapy of exudative AMD;Anti-VEGF-Therapie der exsudativen AMD: Prognostische Faktoren für den Therapieerfolg

Ophthalmologe

Volumn 108, Issue 2, 2011, Pages 124-131

  Heimes, B ^a   Lommatzsch, A ^a   Zeimer, M ^a   Gutfleisch, M ^a   Spital, G ^a   Pauleikhoff, D ^a  

^a ST FRANZISKUS HOSPITAL   (Germany)

Author keywords

Anti VEGF therapy; Autofluorescence; Exudative AMD; Microperimetry; Prognostic factors

Indexed keywords

EID: 79951813072     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-010-2210-z     Document Type: Article

References (15)

1. Ablonczy Z, Crosson CE (2007) VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res 85: 762-771.
2. Boyer DS, Antoszyk AN, Awh CC et al (2007) Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114: 246-252.
3. Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444.
4. Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116: 57-65.
5. Chang TS, Bressler NM, Fine JT et al (2007) Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 125: 1460-1469.
6. Dandekar SS, Jenkins SA, Peto T et al (2005) Autofluorescence imaging of choroidal neovascularization due to age-related macular degeneration. Arch Ophthalmol 123: 1507-1513.
7. Fung AE, Lalwani GA, Rosenfeld PJ et al (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143: 566-583.
8. Heimes B, Lommatzsch A, Zeimer M et al (2008) Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD. Graefes Arch Clin Exp Ophthalmol 246: 1229-1234.
9. Kaiser PK, Blodi BA, Shapiro H et al (2007) Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114: 1868-1875.
10. Kaiser PK, Brown DM, Zhang K et al (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144: 850-857.
11. McBain VA, Townend J, Lois N (2006) Fundus autofluorescence in exudative age-related macular degeneration. Br J Ophthalmol 91(4): 491-496.
12. Regillo CD, Brown DM, Abraham P et al (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145: 239-248.
13. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
14. Vaclavik V, Vujosevic S, Dandekar SS et al (2008) Autofluorescence imaging in age-related macular degeneration complicated by choroidal neovascularization: a prospective study. Ophthalmology 115: 342-346.
15. Vujosevic S, Vaclavik V, Bird AC et al (2007) Combined grading for choroidal neovascularisation: colour, fluorescein angiography and autofluorescence images. Graefes Arch Clin Exp Ophthalmol 245: 1453-1460.